Fighting with the enemy's weapons? The role of costimulatory molecules in HIV

Current Molecular Medicine

Volumn 11, Issue 3, 2011, Pages 172-196

  de Keersmaecker, B ^a   Thielemans, K ^a   Aerts, J L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

Antigen presenting cells; Co inhibitory molecules; Costimulatory molecules; HIV; T cells; T cell exhaustion

Indexed keywords

ALPHA INTERFERON ANTIBODY; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; B7 ANTIGEN; CD134 ANTIGEN; CD137 ANTIGEN; CD137 LIGAND; CD27 ANTIGEN; CD28 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD70 ANTIGEN; CD86 ANTIGEN; CYTOKINE ANTIBODY; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; FAS LIGAND; HERPESVIRUS ENTRY MEDIATOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERFERON ANTIBODY; INTERLEUKIN 12; OSTEOCLAST DIFFERENTIATION FACTOR; OX40 LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT FAS LIGAND ANTIBODY; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND ANTIBODY; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIVIRAL THERAPY; APOPTOSIS; BINDING SITE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNOSTIMULATION; LIGAND BINDING; LYMPHOCYTE ACTIVATION; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; VIRUS IMMUNITY;

EID: 79953323073     PISSN: 15665240     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652411795243397     Document Type: Review

References (340)

1. Bretscher P, Cohn M. A theory of self-nonself discrimination. Science 1970; 169(950): 1042-9.
2. Curtsinger J, Mescher M. Inflammatory cytokines as a third signal for T cell activation. Curr Opin Immunol 2010; 22(3): 333-40.
3. Jenkins M, Chen C, Jung G, Mueller D, Schwartz R. Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody. J Immunol 1990; 144(1): 16-22.
4. Gravestein L, Borst J. Tumor necrosis factor receptor family members in the immune system. Semin Immunol 1998; 10(6): 423-34.
5. Screaton G, Xu X. T cell life and death signalling via TNF-receptor family members. Curr Opin Immunol 2000; 12(3): 316-22.
6. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009; 9(4): 271-85.
7. Sharpe A, Freeman G. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2(2): 116-26.
8. Linsley P, Brady W, Urnes M, Grosmaire L, Damle N, Ledbetter J. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991; 174(3): 561-9.
9. Waterhouse P, Penninger J, Timms E, Wakeham A, Shahinian A, Lee K, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 1995; 270(5238): 985-8.
10. Nurieva R, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of immune tolerance and function. Immunol Rev 2009; 229(1): 88-100.
11. Pentcheva-Hoang T, Corse E, Allison J. Negative regulators of T-cell activation: potential targets for therapeutic intervention in cancer, autoimmune disease, and persistent infections. Immunol Rev 2009; 229(1): 67-87.
12. Orabona C, Grohmann U, Belladonna M, Fallarino F, Vacca C, Bianchi R, et al. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat Immunol 2004; 5(11): 1134-42.
13. Kuipers H, Muskens F, Willart M, et al. Contribution of the PD-1 ligands/PD-1 signaling pathway to dendritic cell-mediated CD4+ T cell activation. Eur J Immunol 2006; 36(9): 2472-82.
14. Grohmann U, Volpi C, Fallarino F, et al. Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med 2007; 13(5): 579-86.
15. Wang C, Wen T, Routy J, Bernard N, Sekaly R, Watts T. 4-1BBL induces TNF receptor-associated factor 1-dependent Bim modulation in human T cells and is a critical component in the costimulation-dependent rescue of functionally impaired HIV-specific CD8 T cells. J Immunol 2007; 179(12): 8252-63.
16. Kaufmann D, Walker B. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009; 182(10): 5891-7.
17. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214(2): 231-41.
18. Xu X, Screaton G, Gotch F, et al. Evasion of cytotoxic T lymphocyte (CTL) responses by nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells. J Exp Med 1997; 186(1): 7-16.
19. Badley A, Pilon A, Landay A, Lynch D. Mechanisms of HIV-associated lymphocyte apoptosis. Blood 2000; 96(9): 2951-64.
20. Yang Y, Tikhonov I, Ruckwardt T, et al. Monocytes treated with human immunodeficiency virus Tat kill uninfected CD4(+) cells by a tumor necrosis factor-related apoptosis-induced ligand-mediated mechanism. J Virol 2003; 77(12): 6700-8.
21. Boya P, Pauleau A, Poncet D, Gonzalez-Polo R, Zamzami N, Kroemer G. Viral proteins targeting mitochondria: controlling cell death. Biochim Biophys Acta 2004; 1659(2-3): 178-89.
22. Katsikis P, Wunderlich E, Smith C, Herzenberg L. Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals. J Exp Med 1995; 181(6): 2029-36.
23. Strauss G, Lindquist J, Arhel N, et al. CD95 co-stimulation blocks activation of naive T cells by inhibiting T cell receptor signaling. J Exp Med 2009; 206(6): 1379-93.
24. Lu G, Janjic B, Janjic J, Whiteside T, Storkus W, Vujanovic N. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-alpha(1)beta(2), Fas ligand, and TNF-related apoptosis-inducing ligand. J Immunol 2002; 168(4): 1831-9.
25. Trambas C, Griffiths G. Delivering the kiss of death. Nat Immunol 2003; 4(5): 399-403.
26. Schulte M, Reiss K, Lettau M, et al. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ 2007; 14(5): 1040-9.
27. Sousa A, Chaves A, Doroana M, Antunes F, Victorino R. Early reduction of the over-expression of CD40L, OX40 and Fas on T cells in HIV-1 infection during triple anti-retroviral therapy: possible implications for lymphocyte traffic and functional recovery. Clin Exp Immunol 1999; 116(2): 307-15.
28. Meyaard L, Otto S, Jonker R, Mijnster M, Keet R, Miedema F. Programmed death of T cells in HIV-1 infection. Science 1992; 257(5067): 217-9.
29. Boise L, Thompson C. Hierarchical control of lymphocyte survival. Science 1996; 274(5284): 67-8.
30. Giri M, Nebozyhn M, Raymond A, et al. Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance. J Immunol 2009; 182(7): 4459-70.
31. Badley A, Dockrell D, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest 1998; 102(1): 79-87.
32. Dyrhol-Riise A, Stent G, Røsok B, Voltersvik P, Olofsson J, Asjö B. The Fas/FasL system and T cell apoptosis in HIV-1-infected lymphoid tissue during highly active antiretroviral therapy. Clin Immunol 2001; 101(2): 169-79.
33. Gasper-Smith N, Crossman D, Whitesides J, et al. Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. J Virol 2008; 82(15): 7700-10.
34. Quaranta M, Mattioli B, Giordani L, Viora M. HIV-1 Nef equips dendritic cells to reduce survival and function of CD8+ T cells: a mechanism of immune evasion. FASEB J 2004; 18(12): 1459-61.
35. Mitra D, Steiner M, Lynch D, Staiano-Coico L, Laurence J. HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology 1996; 87(4): 581-5.
36. Westendorp M, Frank R, Ochsenbauer C, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995; 375(6531): 497-500.
37. Xu X, Laffert B, Screaton G, et al. Induction of Fas ligand expression by HIV involves the interaction of Nef with the T cell receptor zeta chain. J Exp Med 1999; 189(9): 1489-96.
38. Herbeuval J, Nilsson J, Boasso A, et al. HAART reduces death ligand but not death receptors in lymphoid tissue of HIV-infected patients and simian immunodeficiency virus-infected macaques. AIDS 2009; 23(1): 35-40.
39. Badley A, Dockrell D, Simpson M, et al. Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor. J Exp Med 1997; 185(1): 55-64.
40. Oyaizu N, Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis: a possible mechanism of bystander cell death in HIV infection. J Immunol 1997; 158(5): 2456-63.
41. De Milito A, Mörch C, Sönnerborg A, Chiodi F. Loss of memory (CD27) B lymphocytes in HIV-1 infection. AIDS 2001; 15(8): 957-64.
42. Moir S, Malaspina A, Pickeral O, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004; 200(7): 587-99.
43. Estaquier J, Idziorek T, Zou W, et al. T helper type 1/T helper type 2 cytokines and T cell death: preventive effect of interleukin 12 on activation-induced and CD95 (FAS/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons. J Exp Med 1995; 182(6): 1759-67.
44. Salvato M, Yin C, Yagita H, et al. Attenuated disease in SIV-infected macaques treated with a monoclonal antibody against FasL. Clin Dev Immunol 2007; 2007: 93462.
45. Poonia B, Salvato M, Yagita H, Maeda T, Okumura K, Pauza C. Treatment with anti-FasL antibody preserves memory lymphocytes and virus-specific cellular immunity in macaques challenged with simian immunodeficiency virus. Blood 2009; 114(6): 1196-204.
46. Sheridan J, Marsters S, Pitti R, et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 1997; 277(5327): 818-21.
47. Falschlehner C, Emmerich C, Gerlach B, Walczak H. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol 2007; 39(7-8): 1462-75.
48. Herbeuval J, Grivel J, Boasso A, et al. CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon-dependent, TRAIL/DR5-mediated apoptosis. Blood 2005; 106(10): 3524-31.
49. Stary G, Klein I, Kohlhofer S, et al. Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patients. Blood 2009; 114(18): 3854-63.
50. Herbeuval J, Hardy A, Boasso A, et al. Regulation of TNF-related apoptosis-inducing ligand on primary CD4+ T cells by HIV-1: role of type I IFN-producing plasmacytoid dendritic cells. Proc Natl Acad Sci USA 2005; 102(39): 13974-9.
51. Fitzgerald-Bocarsly P, Jacobs E. Plasmacytoid dendritic cells in HIV infection: striking a delicate balance. J Leukoc Biol 2010; 87(4): 609-20.
52. Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176(1): 248-55.
53. Lichtner M, Marañón C, Vidalain P, et al. HIV type 1-infected dendritic cells induce apoptotic death in infected and uninfected primary CD4 T lymphocytes. AIDS Res Hum Retroviruses 2004; 20(2): 175-82.
54. Miura Y, Misawa N, Maeda N, et al. Critical contribution of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) to apoptosis of human CD4+ T cells in HIV-1-infected hu-PBL-NOD-SCID mice. J Exp Med 2001; 193(5): 651-60.
55. Gravestein L, Amsen D, Boes M, Calvo C, Kruisbeek A, Borst J. The TNF receptor family member CD27 signals to Jun N-terminal kinase via Traf-2. Eur J Immunol 1998; 28(7): 2208-16.
56. Akiba H, Nakano H, Nishinaka S, Shindo M, Kobata T, Atsuta M, et al. CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem 1998; 273(21): 13353-8.
57. de Jong R, Loenen W, Brouwer M, et al. Regulation of expression of CD27, a T cell-specific member of a novel family of membrane receptors. J Immunol 1991; 146(8): 2488-94.
58. Bowman M, Crimmins M, Yetz-Aldape J, Kriz R, Kelleher K, Herrmann S. The cloning of CD70 and its identification as the ligand for CD27. J Immunol 1994; 152(4): 756-61.
59. Tesselaar K, Gravestein L, van Schijndel G, Borst J, van Lier R. Characterization of murine CD70, the ligand of the TNF receptor family member CD27. J Immunol 1997; 159(10): 4959-65.
60. Ramakrishnan P, Wang W, Wallach D. Receptor-specific signaling for both the alternative and the canonical NF-kappaB activation pathways by NF-kappaB-inducing kinase. Immunity 2004; 21(4): 477-89.
61. van Oosterwijk M, Juwana H, Arens R, et al. CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development. Int Immunol 2007; 19(6): 713-8.
62. Widney D, Gundapp G, Said J, et al. Aberrant expression of CD27 and soluble CD27 (sCD27) in HIV infection and in AIDS-associated lymphoma. Clin Immunol 1999; 93(2): 114-23.
63. De Milito A, Aleman S, Marenzi R, et al. Plasma levels of soluble CD27: a simple marker to monitor immune activation during potent antiretroviral therapy in HIV-1-infected subjects. Clin Exp Immunol 2002; 127(3): 486-94.
64. Kornbluth R. An expanding role for CD40L and other tumor necrosis factor superfamily ligands in HIV infection. J Hematother Stem Cell Res 2002; 11(5): 787-801.
65. Wolthers K, Otto S, Lens S, et al. Increased expression of CD80, CD86 and CD70 on T cells from HIV-infected individuals upon activation in vitro: regulation by CD4+ T cells. Eur J Immunol 1996; 26(8): 1700-6.
66. Appay V, Nixon D, Donahoe S, Gillespie G, Dong T, King A, et al. HIV-specific CD8(+) T cells produce antiviral cytokines but are impaired in cytolytic function. J Exp Med 2000; 192(1): 63-75.
67. van Baarle D, Kostense S, Hovenkamp E, et al. Lack of Epstein-Barr virus- and HIV-specific CD27- CD8+ T cells is associated with progression to viral disease in HIV-infection. AIDS 2002; 16(15): 2001-11.
68. Kalams S, Walker B. The critical need for CD4 help in maintaining effective cytotoxic T lymphocyte responses. J Exp Med 1998; 188(12): 2199-204.
69. Ochsenbein A, Riddell S, Brown M, et al. CD27 expression promotes long-term survival of functional effector-memory CD8+ cytotoxic T lymphocytes in HIV-infected patients. J Exp Med 2004; 200(11): 1407-17.
70. Wu J, Dyer W, Chrisp J, Belov L, Wang B, Saksena N. Longitudinal microarray analysis of cell surface antigens on peripheral blood mononuclear cells from HIV+ individuals on highly active antiretroviral therapy. Retrovirology 2008; 5: 24.
71. Luciano A, Lederman M, Valentin-Torres A, Bazdar D, Sieg S. Impaired induction of CD27 and CD28 predicts naive CD4 T cell proliferation defects in HIV disease. J Immunol 2007; 179(6): 3543-9.
72. Nagase H, Agematsu K, Kitano K.T, et al. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol 2001; 100(2): 250-9.
73. Nolte M, van Olffen R, van Gisbergen K, van Lier R. Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology. Immunol Rev 2009; 229(1): 216-31.
74. Titanji K, Sammicheli S, De Milito A, et al. Altered distribution of natural killer cell subsets identified by CD56, CD27 and CD70 in primary and chronic human immunodeficiency virus-1 infection. Immunology 2008; 123(2): 164-70.
75. Croft M, So T, Duan W, Soroosh P. The significance of OX40 and OX40L to T-cell biology and immune disease. Immunol Rev 2009; 229(1): 173-91.
76. Godfrey W, Fagnoni F, Harara M, Buck D, Engleman E. Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med 1994; 180(2): 757-62.
77. Flynn S, Toellner K, Raykundalia C, Goodall M, Lane P. CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med 1998; 188(2): 297-304.
78. Ito T, Amakawa R, Inaba M, et al. Plasmacytoid dendritic cells regulate Th cell responses through OX40 ligand and type I IFNs. J Immunol 2004; 172(7): 4253-9.
79. Burrell B, Lu G, Li X, Bishop D. OX40 costimulation prevents allograft acceptance induced by CD40-CD40L blockade. J Immunol 2009; 182(1): 379-90.
80. Bansal-Pakala P, Halteman B, Cheng M, Croft M. Costimulation of CD8 T cell responses by OX40. J Immunol 2004; 172(8): 4821-5.
81. Hendriks J, Xiao Y, Rossen J, et al. During viral infection of the respiratory tract, CD27, 4-1BB, and OX40 collectively determine formation of CD8+ memory T cells and their capacity for secondary expansion. J Immunol 2005; 175(3): 1665-76.
82. Song A, Tang X, Harms K, Croft M. OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen. J Immunol 2005; 175(6): 3534-41.
83. Nagar M, Jacob-Hirsch J, Vernitsky H, et al. TNF Activates a NF-{kappa}B-Regulated Cellular Program in Human CD45RA- Regulatory T Cells that Modulates Their Suppressive Function. J Immunol 2010; 184(7): 3570-81.
84. Valzasina B, Guiducci C, Dislich H, Killeen N, Weinberg A, Colombo M. Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood 2005; 105(7): 2845-51.
85. Brocker T, Gulbranson-Judge A, Flynn S, Riedinger M, Raykundalia C, Lane P. CD4 T cell traffic control: in vivo evidence that ligation of OX40 on CD4 T cells by OX40-ligand expressed on dendritic cells leads to the accumulation of CD4 T cells in B follicles. Eur J Immunol 1999; 29(5): 1610-6.
86. Stüber E, Neurath M, Calderhead D, Fell H, Strober W. Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity 1995; 2(5): 507-21.
87. Kondo K, Okuma K, Tanaka R, et al. Requirements for the functional expression of OX40 ligand on human activated CD4+ and CD8+ T cells. Hum Immunol 2007; 68(7): 563-71.
88. Stüber E, Strober W. The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response. J Exp Med 1996; 183(3): 979-89.
89. Yu Q, Yue F, Gu X, Schwartz H, Kovacs C, Ostrowski M. OX40 ligation of CD4+ T cells enhances virus-specific CD8+ T cell memory responses independently of IL-2 and CD4+ T regulatory cell inhibition. J Immunol 2006; 176(4): 2486-95.
90. Zhang R, Fichtenbaum C, Hildeman D, Lifson J, Chougnet C. CD40 ligand dysregulation in HIV infection: HIV glycoprotein 120 inhibits signaling cascades upstream of CD40 ligand transcription. J Immunol 2004; 172(4): 2678-86.
91. Kassu A, D'Souza M, O'Connor B, et al. Decreased 4-1BB expression on HIV-specific CD4+ T cells is associated with sustained viral replication and reduced IL-2 production. Clin Immunol 2009; 132(2): 234-45.
92. Liu J, Ngai N, Stone G, Yue F, Ostrowski M. The adjuvancy of OX40 ligand (CD252) on an HIV-1 canarypox vaccine. Vaccine 2009; 27(37): 5077-84.
93. Serghides L, Bukczynski J, Wen T, et al. Evaluation of OX40 ligand as a costimulator of human antiviral memory CD8 T cell responses: comparison with B7.1 and 4-1BBL. J Immunol 2005; 175(10): 6368-77.
94. Takahashi Y, Tanaka Y, Yamashita A, Koyanagi Y, Nakamura M, Yamamoto N. OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection. J Virol 2001; 75(15): 6748-57.
95. Jourdan P, Vendrell J, Huguet M, et al. Cytokines and cell surface molecules independently induce CXCR4 expression on CD4+ CCR7+ human memory T cells. J Immunol 2000; 165(2): 716-24.
96. Tanaka R, Takahashi Y, Kodama A, Saito M, Ansari A, Tanaka Y. Suppression of CCR5-tropic HIV type 1 infection by OX40 stimulation via enhanced production of β-chemokines. AIDS Res Hum Retroviruses 2010; 26(10): 1147-54.
97. Takahashi Y, Tanaka R, Yamamoto N, Tanaka Y. Enhancement of OX40-induced apoptosis by TNF coactivation in OX40-expressing T cell lines in vitro leading to decreased targets for HIV type 1 production. AIDS Res Hum Retroviruses 2008; 24(3): 423-35.
98. Arch R, Thompson C. 4-1BB and Ox40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol Cell Biol 1998; 18(1): 558-65.
99. Jang I, Lee Z, Kim Y, Kim S, Kwon B. Human 4-1BB (CD137) signals are mediated by TRAF2 and activate nuclear factor-kappa B. Biochem Biophys Res Commun 1998; 242(3): 613-20.
100. Lee H, Park S, Choi B, Kim H, Nam K, Kwon B. 4-1 BB promotes the survival of CD8+ T lymphocytes by increasing expression of Bcl-xL and Bfl-1. J Immunol 2002; 169(9): 4882-8.
101. Sabbagh L, Pulle G, Liu Y, Tsitsikov E, Watts T. ERK-dependent Bim modulation downstream of the 4-1BB-TRAF1 signaling axis is a critical mediator of CD8 T cell survival in vivo. J Immunol 2008; 180(12): 8093-101.
102. Kwon B, Lee H, Kwon B. New insights into the role of 4-1BB in immune responses: beyond CD8+ T cells. Trends Immunol 2002; 23(8): 378-80.
103. Heinisch I, Daigle I, Knöpfli B, Simon H. CD137 activation abrogates granulocyte-macrophage colony-stimulating factor-mediated anti-apoptosis in neutrophils. Eur J Immunol 2000; 30(12): 3441-6.
104. Huang Q, Liu D, Majewski P, et al. The plasticity of dendritic cell responses to pathogens and their components. Science 2001; 294(5543): 870-5.
105. Futagawa T, Akiba H, Kodama T, et al. Expression and function of 4-1 BB and 4-1 BB ligand on murine dendritic cells. Int Immunol 2002; 14(3): 275-86.
106. Bukczynski J, Wen T, Watts T. Costimulation of human CD28- T cells by 4-1BB ligand. Eur J Immunol 2003; 33(2): 446-54.
107. Bertram E, Lau P, Watts T. Temporal segregation of 4-1BB versus CD28-mediated costimulation: 4-1 BB ligand influences T cell numbers late in the primary response and regulates the size of the T cell memory response following influenza infection. J Immunol 2002; 168(8): 3777-85.
108. Dawicki W, Bertram E, Sharpe A, Watts T. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses. J Immunol 2004; 173(10): 5944-51.
109. Gramaglia I, Cooper D, Miner K, Kwon B, Croft M. Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand. Eur J Immunol 2000; 30(2): 392-402.
110. Cannons J, Lau P, Ghumman B, et al. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy. J Immunol 2001; 167(3): 1313-24.
111. Wen T, Bukczynski J, Watts T. 4-1 BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function. J Immunol 2002; 168(10): 4897-906.
112. Bansal-Pakala P, Croft M. Defective T cell priming associated with aging can be rescued by signaling through 4-1BB (CD137). J Immunol 2002; 169(9): 5005-9.
113. Dawicki W, Watts T. Expression and function of 4-1BB during CD4 versus CD8 T cell responses in vivo. Eur J Immunol 2004; 34(3): 743-51.
114. Kim Y, Choi B, Kang W, et al. IFN-gamma-indoleamine-2,3 dioxygenase acts as a major suppressive factor in 4-1BB-mediated immune suppression in vivo. J Leukoc Biol 2009; 85(5): 817-25.
115. Sharma R, Elpek K, Yolcu E, et al. Costimulation as a platform for the development of vaccines: a peptide-based vaccine containing a novel form of 4-1BB ligand eradicates established tumors. Cancer Res 2009; 69(10): 4319-26.
116. Choi B, Kim Y, Kwon P, Lee S, Kang S, Kim M, et al. 4-1BB functions as a survival factor in dendritic cells. J Immunol 2009; 182(7): 4107-15.
117. Pauly S, Broll K, Wittmann M, Giegerich G, Schwarz H. CD137 is expressed by follicular dendritic cells and costimulates B lymphocyte activation in germinal centers. J Leukoc Biol 2002; 72(1): 35-42.
118. Zhang X, Voskens C, Sallin M, et al. CD137 promotes proliferation and survival of human B cells. J Immunol 2010; 184(2): 787-95.
119. Baessler T, Charton J, Schmiedel B, et al. CD137 ligand mediates opposite effects in human and mouse NK cells and impairs NK cell reactivity against human acute myeloid leukemia cells Blood 2009; 115(15): 3058-69
120. Choi B, Bae J, Choi E, et al. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004; 75(5): 785-91.
121. Harrison J, Bertram E, Boyle D, Coupar B, Ranasinghe C, Ramshaw I. 4-1BBL coexpression enhances HIV-specific CD8 T cell memory in a poxvirus prime-boost vaccine. Vaccine 2006; 24(47-48): 6867-74.
122. Ganguly S, Liu J, Pillai V, Mittler R, Amara R. Adjuvantive effects of anti-4-1BB agonist Ab and 4-1BBL DNA for a HIV-1 Gag DNA vaccine: different effects on cellular and humoral immunity. Vaccine 2010; 28(5): 1300-9.
123. Bukczynski J, Wen T, Wang C, et al. Enhancement of HIV-specific CD8 T cell responses by dual costimulation with CD80 and CD137L. J Immunol 2005; 175(10): 6378-89.
124. Brinchmann J, Dobloug J, Heger B, Haaheim L, Sannes M, Egeland T. Expression of costimulatory molecule CD28 on T cells in human immunodeficiency virus type 1 infection: functional and clinical correlations. J Infect Dis 1994; 169(4): 730-8.
125. Wang S, Kim Y, Bick C, Kim S, Kwon B. The potential roles of 4-1BB costimulation in HIV type 1 infection. AIDS Res Hum Retroviruses 1998; 14(3): 223-31.
126. Schönbeck U, Mach F, Libby P. CD154 (CD40 ligand). Int J Biochem Cell Biol 2000; 32(7): 687-93.
127. van Kooten C, Banchereau J. CD40-CD40 ligand. J Leukoc Biol 2000; 67(1): 2-17.
128. Huang X, Fan Z, Zheng L, et al. Priming of human immunodeficiency virus type 1 (HIV-1)-specific CD8+ T cell responses by dendritic cells loaded with HIV-1 proteins. J Infect Dis 2003; 187(2): 315-9.
129. Caux C, Massacrier C, Vanbervliet B, et al. Activation of human dendritic cells through CD40 cross-linking. J Exp Med 1994; 180(4): 1263-72.
130. Brossart P, Grünebach F, Stuhler G, et al. Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 1998; 92(11): 4238-47.
131. Chougnet C, Cohen S, Kawamura T, et al. Normal immune function of monocyte-derived dendritic cells from HIV-infected individuals: implications for immunotherapy. J Immunol 1999; 163(3): 1666-73.
132. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996; 184(2): 747-52.
133. Kuniyoshi J, Kuniyoshi C, Lim A, et al. Dendritic cell secretion of IL-15 is induced by recombinant huCD40LT and augments the stimulation of antigen-specific cytolytic T cells. Cell Immunol 1999; 193(1): 48-58.
134. di Marzio P, Mariani R, Lui R, Thomas E, Landau N. Soluble CD40 ligand induces beta-chemokine production by macrophages and resistance to HIV-1 entry. Cytokine 2000; 12(10): 1489-95.
135. Serra P, Amrani A, Yamanouchi J, et al. CD40 ligation releases immature dendritic cells from the control of regulatory CD4+CD25+ T cells. Immunity 2003; 19(6): 877-89.
136. Misra N, Bayry J, Lacroix-Desmazes S, Kazatchkine M, Kaveri S. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172(8): 4676-80.
137. Kornbluth R. The emerging role of CD40 ligand in HIV infection. J Leukoc Biol 2000; 68(3): 373-82.
138. Sipsas N, Sfikakis P, Kontos A, Kordossis T. Levels of soluble CD40 ligand (CD154) in serum are increased in human immunodeficiency virus type 1-infected patients and correlate with CD4(+) T-cell counts. Clin Diagn Lab Immunol 2002; 9(3): 558-61.
139. Vanham G, Penne L, Devalck J, et al. Decreased CD40 ligand induction in CD4 T cells and dysregulated IL-12 production during HIV infection. Clin Exp Immunol 1999; 117(2): 335-42.
140. Subauste C, Wessendarp M, Portilllo J, et al. Pathogen-specific induction of CD154 is impaired in CD4+ T cells from human immunodeficiency virus-infected patients. J Infect Dis 2004; 189(1): 61-70.
141. Müller F, Aukrust P, Nordoy I, Froland S. Possible role of interleukin-10 (IL-10) and CD40 ligand expression in the pathogenesis of hypergammaglobulinemia in human immunodeficiency virus infection: modulation of IL-10 and Ig production after intravenous Ig infusion. Blood 1998; 92(10): 3721-9.
142. Chirmule N, McCloskey T, Hu R, Kalyanaraman V, Pahwa S. HIV gp120 inhibits T cell activation by interfering with expression of costimulatory molecules CD40 ligand and CD80 (B71). J Immunol 1995; 155(2): 917-24.
143. Subauste C, Subauste A, Wessendarp M. Role of CD40-dependent down-regulation of CD154 in impaired induction of CD154 in CD4(+) T cells from HIV-1-infected patients. J Immunol 2007; 178(3): 1645-53.
144. Chougnet C, Thomas E, Landay A, et al. CD40 ligand and IFN-gamma synergistically restore IL-12 production in HIV-infected patients. Eur J Immunol 1998; 28(2): 646-56.
145. Loré K, Sönnerborg A, Broström C, et al. Accumulation of DC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86 expression in lymphoid tissue during acute HIV-1 infection. AIDS 2002; 16(5): 683-92.
146. Muthumani K, Hwang D, Choo A, et al. HIV-1 Vpr inhibits the maturation and activation of macrophages and dendritic cells in vitro. Int Immunol 2005; 17(2): 103-16.
147. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood 2003; 101(11): 4505-11.
148. Donaghy H, Pozniak A, Gazzard B, et al. Loss of blood CD11c(+) myeloid and CD11c(-) plasmacytoid dendritic cells in patients with HIV-1 infection correlates with HIV-1 RNA virus load. Blood 2001; 98(8): 2574-6.
149. Chehimi J, Campbell D, Azzoni L, et al. Persistent decreases in blood plasmacytoid dendritic cell number and function despite effective highly active antiretroviral therapy and increased blood myeloid dendritic cells in HIV-infected individuals. J Immunol 2002; 168(9): 4796-801.
150. Nchinda G, Amadu D, Trumpfheller C, Mizenina O, Uberla K, Steinman R. Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells. Proc Natl Acad Sci USA 2010; 107(9): 4281-6.
151. Vingerhoets J, Kestens L, Penne G, et al. CD8+ cells and not CD4+ T cells are hyporesponsive to CD28- and CD40L-mediated activation in HIV-infected subjects. Clin Exp Immunol 1997; 107(3): 440-7.
152. Manis J, Tian M, Alt F. Mechanism and control of class-switch recombination. Trends Immunol 2002; 23(1): 31-9.
153. Qiao X, He B, Chiu A, Knowles D, Chadburn A, Cerutti A. Human immunodeficiency virus 1 Nef suppresses CD40-dependent immunoglobulin class switching in bystander B cells. Nat Immunol 2006; 7(3): 302-10.
154. Martin G, Tremblay M. HLA-DR, ICAM-1, CD40, CD40L, and CD86 are incorporated to a similar degree into clinical human immunodeficiency virus type 1 variants expanded in natural reservoirs such as peripheral blood mononuclear cells and human lymphoid tissue cultured ex vivo. Clin Immunol 2004; 111(3): 275-85.
155. Martin G, Roy J, Barat C, Ouellet M, Gilbert C, Tremblay M. Human immunodeficiency virus type 1-associated CD40 ligand transactivates B lymphocytes and promotes infection of CD4+ T cells. J Virol 2007; 81(11): 5872-81.
156. Kinter A, Catanzaro A, Monaco J, et al. CC-chemokines enhance the replication of T-tropic strains of HIV-1 in CD4(+) T cells: role of signal transduction. Proc Natl Acad Sci USA 1998; 95(20): 11880-5.
157. Kornbluth R, Kee K, Richman D. CD40 ligand (CD154) stimulation of macrophages to produce HIV-1-suppressive beta-chemokines. Proc Natl Acad Sci USA 1998; 95(9): 5205-10.
158. Bergamini A, Bolacchi F, Pesce C, et al. Increased CD4 and CCR5 expression and human immunodeficiency virus type 1 entry in CD40 ligand-stimulated macrophages. J Infect Dis 2002; 185(11): 1567-77.
159. Ellmark P, Andersson H, Abayneh S, Fenyö E, Borrebaeck C. Identification of a strongly activating human anti-CD40 antibody that suppresses HIV type 1 infection. AIDS Res Hum Retroviruses 2008; 24(3): 367-73.
160. Mueller C, Rissoan M, Salinas B, et al. Polymerase chain reaction selects a novel disintegrin proteinase from CD40-activated germinal center dendritic cells. J Exp Med 1997; 186(5): 655-63.
161. Papadopoulos E, Sassetti C, Saeki H, et al. Fractalkine, a CX3C chemokine, is expressed by dendritic cells and is up-regulated upon dendritic cell maturation. Eur J Immunol 1999; 29(8): 2551-9.
162. Pal R, Garzino-Demo A, Markham P, et al. Inhibition of HIV-1 infection by the beta-chemokine MDC. Science 1997; 278(5338): 695-8.
163. McDyer J, Dybul M, Goletz T, et al. Differential effects of CD40 ligand/trimer stimulation on the ability of dendritic cells to replicate and transmit HIV infection: evidence for CC-chemokine-dependent and -independent mechanisms. J Immunol 1999; 162(6): 3711-7.
164. Gras G, Legendre C, Krzysiek R, Dormont D, Galanaud P, Richard Y. CD40/CD40L interactions and cytokines regulate HIV replication in B cells in vitro. Virology 1996; 220(2): 309-19.
165. Moir S, Lapointe R, Malaspina A, et al. CD40-Mediated induction of CD4 and CXCR4 on B lymphocytes correlates with restricted susceptibility to human immunodeficiency virus type 1 infection: potential role of B lymphocytes as a viral reservoir. J Virol 1999; 73(10): 7972-80.
166. Swingler S, Brichacek B, Jacque J, Ulich C, Zhou J, Stevenson M. HIV-1 Nef intersects the macrophage CD40L signalling pathway to promote resting-cell infection. Nature 2003; 424(6945): 213-9.
167. Ihata A, Watabe S, Sasaki S, et al. Immunomodulatory effect of a plasmid expressing CD40 ligand on DNA vaccination against human immunodeficiency virus type-1. Immunology 1999; 98(3): 436-42.
168. Gómez C, Nájera J, Sánchez R, Jiménez V, Esteban M. Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus vectors MVA and NYVAC expressing HIV antigens. Vaccine 2009; 27(24): 3165-74.
169. Lin F, Peng Y, Jones L, Verardi P, Yilma T. Incorporation of CD40 ligand into the envelope of pseudotyped single-cycle Simian immunodeficiency viruses enhances immunogenicity. J Virol 2009; 83(3): 1216-27.
170. Smed-Sörensen A, Loré K, Walther-Jallow L, Andersson J, Spetz A. HIV-1-infected dendritic cells up-regulate cell surface markers but fail to produce IL-12 p70 in response to CD40 ligand stimulation. Blood 2004; 104(9): 2810-7.
171. Huang X, Fan Z, Borowski L, Rinaldo C. Maturation of dendritic cells for enhanced activation of anti-HIV-1 CD8(+) T cell immunity. J Leukoc Biol 2008; 83(6): 1530-40.
172. Ostrowski M, Justement S, Ehler L, et al. The role of CD4+ T cell help and CD40 ligand in the in vitro expansion of HIV-1-specific memory cytotoxic CD8+ T cell responses. J Immunol 2000; 165(11): 6133-41.
173. Zhang R, Lifson J, Chougnet C. Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions. Blood 2006; 107(5): 1989-95.
174. Routy J, Boulassel M, Yassine-Diab, et al. Immunologic activity and safety of autologous HIV RNA-electroporated dendritic cells in HIV-1 infected patients receiving antiretroviral therapy. Clin Immunol 2010; 134(2): 140-7.
175. Kutsch O, Levy D, Kosloff B, Shaw G, Benveniste E. CD154-CD40-induced reactivation of latent HIV-1 infection. Virology 2003; 314(1): 261-70.
176. Chiu Y, Soros V, Kreisberg J, Stopak K, Yonemoto W, Greene W. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells. Nature 2005; 435(7038): 108-14.
177. Pido-Lopez J, Whittall T, Wang Y, et al. Stimulation of cell surface CCR5 and CD40 molecules by their ligands or by HSP70 up-regulates APOBEC3G expression in CD4(+) T cells and dendritic cells. J Immunol 2007; 178(3): 1671-9.
178. Anderson D, Maraskovsky E, Billingsley W, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390(6656): 175-9.
179. Bachmann M, Wong B, Josien R, Steinman R, Oxenius A, Choi Y. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J Exp Med 1999; 189(7): 1025-31.
180. Josien R, Wong B, Li H, Steinman R, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162(5): 2562-8.
181. Wong B, Josien R, Lee S, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186(12): 2075-80.
182. Gibellini D, Borderi M, De Crignis E, et al. RANKL/OPG/TRAIL plasma levels and bone mass loss evaluation in antiretroviral naive HIV-1-positive men. J Med Virol 2007; 79(10): 1446-54.
183. Konishi M, Takahashi K, Yoshimoto E, Uno K, Kasahara K, Mikasa K. Association between osteopenia/osteoporosis and the serum RANKL in HIV-infected patients. AIDS 2005; 19(11): 1240-1.
184. Fakruddin J, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem 2003; 278(48): 48251-8.
185. Fakruddin J, Laurence J. HIV-1 Vpr enhances production of receptor of activated NF-kappaB ligand (RANKL) via potentiation of glucocorticoid receptor activity. Arch Virol 2005; 150(1): 67-78.
186. Yu Q, Gu J, Kovacs C, Freedman J, Thomas E, Ostrowski M. Cooperation of TNF family members CD40 ligand, receptor activator of NF-kappa B ligand, and TNF-alpha in the activation of dendritic cells and the expansion of viral specific CD8+ T cell memory responses in HIV-1-infected and HIV-1-uninfected individuals. J Immunol 2003; 170(4): 1797-805.
187. Kwon B, Yu K, Ni J, et al. Identification of a novel activation-inducible protein of the tumor necrosis factor receptor superfamily and its ligand. J Biol Chem 1999; 274(10): 6056-61.
188. Kim J, Choi B, Bae J, et al. Cloning and characterization of GITR ligand. Genes Immun 2003; 4(8): 564-9.
189. Tone M, Tone Y, Adams E, et al. Mouse glucocorticoid-induced tumor necrosis factor receptor ligand is costimulatory for T cells. Proc Natl Acad Sci USA 2003; 100(25): 15059-64.
190. Yu K, Kim H, Song S, Min S, Jeong J, Youn B. Identification of a ligand for glucocorticoid-induced tumor necrosis factor receptor constitutively expressed in dendritic cells. Biochem Biophys Res Commun 2003; 310(2): 433-8.
191. Hanabuchi S, Watanabe N, Wang Y, Ito T, Shaw J, Cao W, et al. Human plasmacytoid predendritic cells activate NK cells through glucocorticoid-induced tumor necrosis factor receptor-ligand (GITRL). Blood 2006; 107(9): 3617-23.
192. Shin H, Kim S, Lee M, Suh J, Kwon B, Choi H. Soluble glucocorticoid-induced TNF receptor (sGITR) induces inflammation in mice. Exp Mol Med 2003; 35(5): 358-64.
193. Zhan Y, Funda D, Every A, et al. TCR-mediated activation promotes GITR upregulation in T cells and resistance to glucocorticoid-induced death. Int Immunol 2004; 16(9): 1315-21.
194. Nocentini G, Riccardi C. GITR: a multifaceted regulator of immunity belonging to the tumor necrosis factor receptor superfamily. Eur J Immunol 2005; 35(4): 1016-22.
195. Nocentini G, Riccardi C. GITR: A Modulator of Immune Response and Inflammation. Adv Exp Med Biol 2009; 647: 156-73.
196. McHugh R, Whitters M, Piccirillo C, et al. CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002; 16(2): 311-23.
197. Tuyaerts S, Van Meirvenne S, Bonehill A, et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 2007; 82(1): 93-105.
198. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002; 3(2): 135-42.
199. Stone G, Barzee S, Snarsky V, Kee K, Spina C, Yu X, et al. Multimeric soluble CD40 ligand and GITR ligand as adjuvants for human immunodeficiency virus DNA vaccines. J Virol 2006; 80(4): 1762-72.
200. Suchard MS, Mayne E, Green VA, et al. FOXP3 expression is upregulated in CD4T cells in progressive HIV-1 infection and is a marker of disease severity. PLoS One 2010; 5(7): e11762.
201. Stephens GL, McHugh RS, Whitters MJ, et al. Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol 2004; 173(8): 5008-20.
202. Moreira AP, Cavassani KA, Massafera Tristão FS, et al. CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression. J Immunol 2008; 180(5): 3049-56.
203. D'Elia R, Behnke JM, Bradley JE, Else KJ. Regulatory T cells: a role in the control of helminth-driven intestinal pathology and worm survival. J Immunol 2009; 182(4): 2340-8.
204. Ramirez-Montagut T, Chow A, Hirschhorn-Cymerman D, et al. Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity. J Immunol 2006; 176(11): 6434-42.
205. Côté AL, Zhang P, O'Sullivan JA, et al. Stimulation of the Glucocorticoid-Induced TNF Receptor Family-Related Receptor on CD8 T Cells Induces Protective and High-Avidity T Cell Responses to Tumor-Specific Antigens. J Immunol 2011; 186(1): 275-83.
206. Snell LM, McPherson AJ, Lin GH, et al. CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol 2010; 185(12): 7223-34.
207. Lahey T, Loisel S, Wieland-Alter W. Glucocorticoid-induced tumor necrosis factor receptor family-related protein triggering enhances HIV-specific CD4+ T cell cytokine secretion and protects HIV-specific CD4+ T cells from apoptosis. J Infect Dis 2007; 196(1): 43-9.
208. De Trez C, Schneider K, Potter K, et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol 2008; 180(1): 238-48.
209. Cai G, Freeman G. The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation. Immunol Rev 2009; 229(1): 244-58.
210. Morel Y, Schiano de Colella J, et al. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J Immunol 2000; 165(8): 4397-404.
211. Mauri D, Ebner R, Montgomery R, et al. LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator. Immunity 1998; 8(1): 21-30.
212. Sedy J, Gavrieli M, Potter K, et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 2005; 6(1): 90-8.
213. Tamada K, Shimozaki K, Chapoval A, et al. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J Immunol 2000; 164(8): 4105-10.
214. Wang J, Fu Y. The role of LIGHT in T cell-mediated immunity. Immunol Res 2004; 30(2): 201-14.
215. Duhen T, Pasero C, Mallet F, Barbarat B, Olive D, Costello R. LIGHT costimulates CD40 triggering and induces immunoglobulin secretion; a novel key partner in T cell-dependent B cell terminal differentiation. Eur J Immunol 2004; 34(12): 3534-41.
216. Yu K, Kwon B, Ni J, Zhai Y, Ebner R, Kwon B. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J Biol Chem 1999; 274(20): 13733-6.
217. Schneider K, Potter K, Ware C. Lymphotoxin and LIGHT signaling pathways and target genes. Immunol Rev 2004; 202: 49-66.
218. Steinberg M, Shui J, Ware C, Kronenberg M. Regulating the mucosal immune system: the contrasting roles of LIGHT, HVEM, and their various partners. Semin Immunopathol 2009; 31(2): 207-21.
219. Summers-DeLuca LE, McCarthy DD, Cosovic B, et al. Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function. J Exp Med 2007; 204(5): 1071-81.
220. McCarthy D, Summers-Deluca L, Vu F, Chiu S, Gao Y, Gommerman J. The lymphotoxin pathway: beyond lymph node development. Immunol Res 2006; 35(1-2): 41-54.
221. Harrop J, McDonnell P, Brigham-Burke M, et al. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J Biol Chem 1998; 273(42): 27548-56.
222. Cai G, Anumanthan A, Brown J, Greenfield E, Zhu B, Freeman G. CD160 inhibits activation of human CD4+ T cells through interaction with herpesvirus entry mediator. Nat Immunol 2008; 9(2): 176-85.
223. Vendel A, Calemine-Fenaux J, Izrael-Tomasevic A, Chauhan V, Arnott D, Eaton D. B and T lymphocyte attenuator regulates B cell receptor signaling by targeting Syk and BLNK. J Immunol 2009; 182(3): 1509-17.
224. Han P, Goularte O, Rufner K, Wilkinson B, Kaye J. An inhibitory Ig superfamily protein expressed by lymphocytes and APCs is also an early marker of thymocyte positive selection. J Immunol 2004; 172(10): 5931-9.
225. Hurchla M, Sedy J, Gavrieli M, et al. B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4+ T cells. J Immunol 2005; 174(6): 3377-85.
226. Ware C. Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways. Immunol Rev 2008; 223: 186-201.
227. Maïza H, Leca G, Mansur I, Schiavon V, Boumsell L, Bensussan A. A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity. J Exp Med 1993; 178(3): 1121-6.
228. Bensussan A, Gluckman E, el Marsafy S, et al. BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity. Proc Natl Acad Sci USA 1994; 91(19): 9136-40.
229. Anumanthan A, Bensussan A, Boumsell L, et al. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol 1998; 161(6): 2780-90.
230. Sperling A, Bluestone J. The complexities of T-cell co-stimulation: CD28 and beyond. Immunol Rev 1996; 153: 155-82.
231. Metzler W, Bajorath J, Fenderson W, et al. Solution structure of human CTLA-4 and delineation of a CD80/CD86 binding site conserved in CD28. Nat Struct Biol 1997; 4(7): 527-31.
232. van der Merwe P, Bodian D, Daenke S, Linsley P, Davis S. CD80 (B7-1) binds both CD28 and CTLA-4 with a low affinity and very fast kinetics. J Exp Med 1997; 185(3): 393-403.
233. Parry R, Chemnitz J, Frauwirth K, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25(21): 9543-53.
234. Schneider H, Downey J, Smith A, Zinselmeyer B, Rush C, Brewer J, et al. Reversal of the TCR stop signal by CTLA-4. Science 2006; 313(5795): 1972-5.
235. Fife B, Pauken K, Eagar T, et al. Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. Nat Immunol 2009; 10(11): 1185-92.
236. Fife B, Bluestone J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008; 224: 166-82.
237. Lenschow D, Walunas T, Bluestone J. CD28/B7 system of T cell costimulation. Annu Rev Immunol 1996; 14: 233-58.
238. Frauwirth K, Riley J, Harris M, et al. The CD28 signaling pathway regulates glucose metabolism. Immunity 2002; 16(6): 769-77.
239. Azuma M, Phillips J, Lanier L. CD28- T lymphocytes. Antigenic and functional properties. J Immunol 1993; 150(4): 1147-59.
240. Fagnoni FF, Vescovini R, Mazzola M, et al. Expansion of cytotoxic CD8+ CD28- T cells in healthy ageing people, including centenarians. Immunology 1996; 88(4): 501-7.
241. Czesnikiewicz-Guzik M, Lee WW, Cui D, et al. T cell subset-specific susceptibility to aging. Clin Immunol 2008; 127(1): 107-18.
242. Freeman G, Wherry E, Ahmed R, Sharpe A. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006; 203(10): 2223-7.
243. Larsen C, Ritchie S, Hendrix R, et al. Regulation of immunostimulatory function and costimulatory molecule (B7-1 and B7-2) expression on murine dendritic cells. J Immunol 1994; 152(11): 5208-19.
244. Rattis F, Péguet-Navarro J, Staquet M, et al. Expression and function of B7-1 (CD80) and B7-2 (CD86) on human epidermal Langerhans cells. Eur J Immunol 1996; 26(2): 449-53.
245. Köchli C, Wendland T, Frutig K, Grunow R, Merlin S, Pichler W. CD80 and CD86 costimulatory molecules on circulating T cells of HIV infected individuals. Immunol Lett 1999; 65(3): 197-201.
246. Kuchroo V, Das M, Brown J, et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80(5): 707-18.
247. Sansom D, Manzotti C, Zheng Y. What's the difference between CD80 and CD86? Trends Immunol 2003; 24(6): 314-9.
248. Caruso A, Fiorentini S, Licenziati S, et al. Expansion of rare CD8+ CD28- CD11b- T cells with impaired effector functions in HIV-1-infected patients. J Acquir Immune Defic Syndr 2000; 24(5): 465-74.
249. Appay V, Dunbar P, Callan M, et al. Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002; 8(4): 379-85.
250. Barker E, Bossart K, Fujimura S, Levy J. CD28 costimulation increases CD8+ cell suppression of HIV replication. J Immunol 1997; 159(10): 5123-31.
251. Rehr M, Cahenzli J, Haas A, et al. Emergence of polyfunctional CD8+ T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 2008; 82(7): 3391-404.
252. Swigut T, Shohdy N, Skowronski J. Mechanism for down-regulation of CD28 by Nef. EMBO J 2001; 20(7): 1593-604.
253. Venkatachari N, Majumder B, Ayyavoo V. Human immunodeficiency virus (HIV) type 1 Vpr induces differential regulation of T cell costimulatory molecules: direct effect of Vpr on T cell activation and immune function. Virology 2007; 358(2): 347-56.
254. Jason J, Inge K. Increased expression of CD80 and CD86 in in vitro-infected CD3+ cells producing cytoplasmic HIV type 1 p24. AIDS Res Hum Retroviruses 1999; 15(2): 173-81.
255. Chaudhry A, Das S, Hussain A, et al. The Nef protein of HIV-1 induces loss of cell surface costimulatory molecules CD80 and CD86 in APCs. J Immunol 2005; 175(7): 4566-74.
256. Chaudhry A, Das S, Jameel S, et al. A two-pronged mechanism for HIV-1 Nef-mediated endocytosis of immune costimulatory molecules CD80 and CD86. Cell Host Microbe 2007; 1(1): 37-49.
257. Quaranta M, Tritarelli E, Giordani L, Viora M. HIV-1 Nef induces dendritic cell differentiation: a possible mechanism of uninfected CD4(+) T cell activation. Exp Cell Res 2002; 275(2): 243-54.
258. Kumar A, Angel J, Aucoin S, et al. Dysregulation of B7.2 (CD86) expression on monocytes of HIV-infected individuals is associated with altered production of IL-2. Clin Exp Immunol 1999; 117(1): 84-91.
259. Giguère J, Paquette J, Bounou S, Cantin R, Tremblay M. New insights into the functionality of a virion-anchored host cell membrane protein: CD28 versus HIV type 1. J Immunol 2002; 169(5): 2762-71.
260. Giguère J, Bounou S, Paquette J, Madrenas J, Tremblay M. Insertion of host-derived costimulatory molecules CD80 (B7.1) and CD86 (B7.2) into human immunodeficiency virus type 1 affects the virus life cycle. J Virol 2004; 78(12): 6222-32.
261. Giguere J, Diou J, Madrenas J, Tremblay M. Virus attachment and replication are promoted after acquisition of host CD28 and CD152 by HIV-1. J Infect Dis 2005; 192(7): 1265-8.
262. Bounou S, Dumais N, Tremblay M. Attachment of human immunodeficiency virus-1 (HIV-1) particles bearing host-encoded B7-2 proteins leads to nuclear factor-kappa B- and nuclear factor of activated T cells-dependent activation of HIV-1 long terminal repeat transcription. J Biol Chem 2001; 276(9): 6359-69.
263. Esser M, Graham D, Coren L, et al. Differential incorporation of CD45, CD80 (B7-1), CD86 (B7-2), and major histocompatibility complex class I and II molecules into human immunodeficiency virus type 1 virions and microvesicles: implications for viral pathogenesis and immune regulation. J Virol 2001; 75(13): 6173-82.
264. Li Y, Mak G, Franza BJ. In vitro study of functional involvement of Sp1, NF-kappa B/Rel, and AP1 in phorbol 12-myristate 13-acetate-mediated HIV-1 long terminal repeat activation. J Biol Chem 1994; 269(48): 30616-9.
265. Kinoshita S, Su L, Amano M, Timmerman L, Kaneshima H, Nolan G. The T cell activation factor NF-ATc positively regulates HIV-1 replication and gene expression in T cells. Immunity 1997; 6(3): 235-44.
266. Cook J, Albacker L, August A, Henderson A. CD28-dependent HIV-1 transcription is associated with Vav, Rac, and NF-kappa B activation. J Biol Chem 2003; 278(37): 35812-8.
267. Roy J, Martin G, Giguère J, Bélanger D, Pétrin M, Tremblay M. HIV type 1 can act as an APC upon acquisition from the host cell of peptide-loaded HLA-DR and CD86 molecules. J Immunol 2005; 174(8): 4779-88.
268. Levine B, Mosca J, Riley J, et al. Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. Science 1996; 272(5270): 1939-43.
269. Roederer M, Raju P, Mitra D, Herzenberg L. HIV does not replicate in naive CD4 T cells stimulated with CD3/CD28. J Clin Invest 1997; 99(7): 1555-64.
270. Woods T, Roberts B, Butera S, Folks T. Loss of inducible virus in CD45RA naive cells after human immunodeficiency virus-1 entry accounts for preferential viral replication in CD45RO memory cells. Blood 1997; 89(5): 1635-41.
271. Barker E, Bossart K, Levy J. Differential effects of CD28 costimulation on HIV production by CD4+ cells. J Immunol 1998; 161(11): 6223-7.
272. Mengozzi M, Malipatlolla M, De Rosa S, Herzenberg L, Roederer M. Naive CD4 T cells inhibit CD28-costimulated R5 HIV replication in memory CD4 T cells. Proc Natl Acad Sci USA 2001; 98(20): 11644-9.
273. Carroll R, Riley J, Levine B, et al. Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. Science 1997; 276(5310): 273-6.
274. Asjö B, Cefai D, Debré P, Dudoit Y, Autran B. A novel mode of human immunodeficiency virus type 1 (HIV-1) activation: ligation of CD28 alone induces HIV-1 replication in naturally infected lymphocytes. J Virol 1993; 67(7): 4395-8.
275. Annibaldi A, Sajeva A, Muscolini M, et al. CD28 ligation in the absence of TCR promotes RelA/NF-kappaB recruitment and trans-activation of the HIV-1 LTR. Eur J Immunol 2008; 38(5): 1446-51.
276. Zhou X, Kubo M, Nishitsuji H, et al. Inducible-costimulator-mediated suppression of human immunodeficiency virus type 1 replication in CD4(+) T lymphocytes. Virology 2004; 325(2): 252-63.
277. Nunès J, Klasen S, Ragueneau M, et al. CD28 mAbs with distinct binding properties differ in their ability to induce T cell activation: analysis of early and late activation events. Int Immunol 1993; 5(3): 311-5.
278. Kim J, Bagarazzi M, Trivedi N, et al. Engineering of in vivo immune responses to DNA immunization via codelivery of costimulatory molecule genes. Nat Biotechnol 1997; 15(7): 641-6.
279. Tsuji T, Hamajima K, Ishii N, et al. Immunomodulatory effects of a plasmid expressing B7-2 on human immunodeficiency virus-1-specific cell-mediated immunity induced by a plasmid encoding the viral antigen. Eur J Immunol 1997; 27(3): 782-7.
280. Kim J, Nottingham L, Wilson D, et al. Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. Vaccine 1998; 16(19): 1828-35.
281. Egen J, Kuhns M, Allison J. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3(7): 611-8.
282. Greenwald R, Freeman G, Sharpe A. The B7 family revisited. Annu Rev Immunol 2005; 23: 515-48.
283. Fallarino F, Grohmann U, Hwang K, et al. Modulation of tryptophan catabolism by regulatory T cells. Nat Immunol 2003; 4(12): 1206-12.
284. Steiner K, Waase I, Rau T, Dietrich M, Fleischer B, Bröker B. Enhanced expression of CTLA-4 (CD152) on CD4+ T cells in HIV infection. Clin Exp Immunol 1999; 115(3): 451-7.
285. Leng Q, Bentwich Z, Magen E, Kalinkovich A, Borkow G. CTLA-4 upregulation during HIV infection: association with anergy and possible target for therapeutic intervention. AIDS 2002; 16(4): 519-29.
286. Kaufmann D, Kavanagh D, Pereyra F, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007; 8(11): 1246-54.
287. Kassu A, Marcus R, D'Souza M, et al. Regulation of virus-specific CD4(+) T cell function by multiple costimulatory receptors during chronic HIV infection. J Immunol 2010; 185(5): 3007-18.
288. Andersson J, Boasso A, Nilsson J, et al. The prevalence of regulatory T cells in lymphoid tissue is correlated with viral load in HIV-infected patients. J Immunol 2005; 174(6): 3143-7.
289. Riley J, Schlienger K, Blair P, et al. Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. J Exp Med 2000; 191(11): 1987-97.
290. Chen W, Jin W, Wahl S. Engagement of cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) induces transforming growth factor beta (TGF-beta) production by murine CD4(+) T cells. J Exp Med 1998; 188(10): 1849-57.
291. Li J, Shen X, Hu P, Wang X. Transforming growth factor beta stimulates the human immunodeficiency virus 1 enhancer and requires NF-kappaB activity. Mol Cell Biol 1998; 18(1): 110-21.
292. Phan G, Yang J, Sherry R, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100(14): 8372-7.
293. Elrefaei M, Burke C, Baker C, et al. TGF-beta and IL-10 production by HIV-specific CD8+ T cells is regulated by CTLA-4 signaling on CD4+ T cells. PLoS One 2009; 4(12): e8194.
294. Cecchinato V, Tryniszewska E, Ma Z, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol 2008; 180(8): 5439-47.
295. Hryniewicz A, Boasso A, Edghill-Smith Y, et al. CTLA-4 blockade decreases TGF-beta, IDO, and viral RNA expression in tissues of SIVmac251-infected macaques. Blood 2006; 108(12): 3834-42.
296. O'Day SJ, Maio M, Chiarion-Sileni V, et al. Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study. Ann Oncol 2010; 21(8): 1712-7.
297. Agata Y, Kawasaki A, Nishimura H, et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996; 8(5): 765-72.
298. Okazaki T, Iwai Y, Honjo T. New regulatory co-receptors: inducible co-stimulator and PD-1. Curr Opin Immunol 2002; 14(6): 779-82.
299. Okazaki T, Honjo T. Rejuvenating exhausted T cells during chronic viral infection. Cell 2006; 124(3): 459-61.
300. Petrovas C, Casazza J, Brenchley J, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006; 203(10): 2281-92.
301. Keir M, Francisco L, Sharpe A. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol 2007; 19(3): 309-14.
302. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999; 5(12): 1365-9.
303. Tamura H, Dong H, Zhu G, et al. B7-H1 costimulation preferentially enhances CD28-independent T-helper cell function. Blood 2001; 97(6): 1809-16.
304. Liu J, Hamrouni A, Wolowiec D, et al. Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 2007; 110(1): 296-304.
305. Day C, Kaufmann D, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006; 443(7109): 350-4.
306. Sauce D, Almeida J, Larsen M, et al. PD-1 expression on human CD8 T cells depends on both state of differentiation and activation status. AIDS 2007; 21(15): 2005-13.
307. Muthumani K, Choo A, Shedlock D, et al. Human immunodeficiency virus type 1 Nef induces programmed death 1 expression through a p38 mitogen-activated protein kinase-dependent mechanism. J Virol 2008; 82(23): 11536-44.
308. Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006; 12(10): 1198-202.
309. Zhang J, Zhang Z, Wang X, et al. PD-1 up-regulation is correlated with HIV-specific memory CD8+ T-cell exhaustion in typical progressors but not in long-term nonprogressors. Blood 2007; 109(11): 4671-8.
310. Salisch N, Kaufmann D, Awad A, et al. Inhibitory TCR coreceptor PD-1 is a sensitive indicator of low-level replication of SIV and HIV-1. J Immunol 2010; 184(1): 476-87.
311. Harari A, Cellerai C, Enders F, et al. Skewed association of polyfunctional antigen-specific CD8 T cell populations with HLA-B genotype. Proc Natl Acad Sci USA 2007; 104(41): 16233-8.
312. Elrefaei M, Baker C, Jones N, Bangsberg D, Cao H. Presence of suppressor HIV-specific CD8+ T cells is associated with increased PD-1 expression on effector CD8+ T cells. J Immunol 2008; 180(11): 7757-63.
313. Quigley M, Pereyra F, Nilsson B, et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010; 16(10): 1147-51.
314. D'Souza M, Fontenot A, Mack D, et al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol 2007; 179(3): 1979-87.
315. Venkatachari N, Buchanan W, Ayyavoo V. Human immunodeficiency virus (HIV-1) infection selectively downregulates PD-1 expression in infected cells and protects the cells from early apoptosis in vitro and in vivo. Virology 2008; 376(1): 140-53.
316. Velu V, Kannanganat S, Ibegbu C, et al. Elevated expression levels of inhibitory receptor programmed death 1 on simian immunodeficiency virus-specific CD8 T cells during chronic infection but not after vaccination. J Virol 2007; 81(11): 5819-28.
317. Said E, Dupuy F, Trautmann L, et al. Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection. Nat Med 2010; 16(4): 452-9.
318. Moll M, Kuylenstierna C, Gonzalez V, et al. Severe functional impairment and elevated PD-1 expression in CD1d-restricted NKT cells retained during chronic HIV-1 infection. Eur J Immunol 2009; 39(3): 902-11.
319. Trabattoni D, Saresella M, Biasin M, et al. B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. Blood 2003; 101(7): 2514-20.
320. Rosignoli G, Cranage A, Burton C, et al. Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. AIDS 2007; 21(10): 1379-81.
321. Wang X, Zhang Z, Zhang S, et al. B7-H1 up-regulation impairs myeloid DC and correlates with disease progression in chronic HIV-1 infection. Eur J Immunol 2008; 38(11): 3226-36.
322. Boasso A, Hardy A, Landay A, et al. PDL-1 upregulation on monocytes and T cells by HIV via type I interferon: restricted expression of type I interferon receptor by CCR5-expressing leukocytes. Clin Immunol 2008; 129(1): 132-44.
323. Meier A, Bagchi A, Sidhu H, et al. Upregulation of PD-L1 on monocytes and dendritic cells by HIV-1 derived TLR ligands. AIDS 2008; 22(5): 655-8.
324. Lichterfeld M, Mou D, Cung T, et al. Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood 2008; 112(9): 3679-87.
325. Velu V, Titanji K, Zhu B, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009; 458(7235): 206-10.
326. Macatangay B, Rinaldo C. PD-1 blockade: A promising immunotherapy for HIV? Cellscience 2009; 5(4): 61-5.
327. Franceschini D, Paroli M, Francavilla V, et al. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009; 119(3): 551-64.
328. Radziewicz H, Dunham R, Grakoui A. PD-1 tempers Tregs in chronic HCV infection. J Clin Invest 2009; 119(3): 450-3.
329. Jones RB, Ndhlovu LC, Barbour JD, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008; 205(12): 2763-79.
330. Jin HT, Anderson AC, Tan WG, et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc Natl Acad Sci USA 2010; 107(33): 14733-8.
331. Lucia M, Buonfiglio D, Bottarel F, et al. Expression of the novel T cell activation molecule hpH4 in HIV-infected patients: correlation with disease status. AIDS Res Hum Retroviruses 2000; 16(6): 549-57.
332. Vidric M, Suh W, Dianzani U, Mak T, Watts T. Cooperation between 4-1BB and ICOS in the immune response to influenza virus revealed by studies of CD28/ICOS-deficient mice. J Immunol 2005; 175(11): 7288-96.
333. Serghides L, Vidric M, Watts T. Approaches to studying costimulation of human antiviral T cell responses: prospects for immunotherapeutic vaccines. Immunol Res 2006; 35(1-2):137-50.
334. Arens R, Tesselaar K, Baars P, et al. Constitutive CD27/CD70 interaction induces expansion of effector-type T cells and results in IFNgamma-mediated B cell depletion. Immunity 2001; 15(5): 801-12.
335. Zhu G, Flies D, Tamada K, et al. Progressive depletion of peripheral B lymphocytes in 4-1BB (CD137) ligand/I-Ealpha)-transgenic mice. J Immunol 2001; 167(5): 2671-6.
336. Myers L, Takahashi C, Mittler R, Rossi R, Vella A. Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc Natl Acad Sci USA 2003; 100(9): 5348-53.
337. Wang C, Lin G, McPherson A, Watts T. Immune regulation by 4-1BB and 4-1BBL: complexities and challenges. Immunol Rev 2009; 229(1): 192-215.
338. Weiss L, Donkova-Petrini V, Caccavelli L, Balbo M, Carbonneil C, Levy Y. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood 2004; 104(10): 3249-56.
339. Aandahl E, Michaëlsson J, Moretto W, Hecht F, Nixon D. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78(5): 2454-9.
340. Chase A, Yang H, Zhang H, Blankson J, Siliciano R. Preservation of FoxP3+ regulatory T cells in the peripheral blood of human immunodeficiency virus type 1-infected elite suppressors correlates with low CD4+ T-cell activation. J Virol 2008; 82(17): 8307-15.